Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 11, 2013 (14 years ago)

Lisinopril and Hydrochlorothiazide Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of Foreign Substance: Reports of gray smudges identified as minute stainless steel particulates were found in the recalled tablets by the manufacturer

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS, USP, 20 mg/25 mg, 100 (NDC 60429-046-01) and 1,000 (NDC 60429-046-10) count bottles, Rx only, GSMS Inc., Camarillo, CA

Affected NDCs 60429-0046-01 60429-0046-10

Compare with the code on your package — it is the most precise check available.

Drug: Hydrochlorothiazide Category: Blood Pressure Medication

Recalling firm
Gsms
NDC code
60429-046-01
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-244-2013 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Hydrochlorothiazide recalls

See all
Class II · Moderate risk

Lisinopril and Hydrochlorothiazide Tablets USP 20mg/12.5mg

Product Mix Up: This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg.

Ongoing Labeling / mix-up Lupin Pharmaceuticals Inc. NDC 68180-519-01 D-0532-2025

Other particulate / foreign matter recalls from 2013

All particulate / foreign matter recalls
Class II · Moderate risk

Carisoprodol Tablets

Presence of Foreign Substance; metal particulates were visually observed in the tablets.

Terminated Particulate / foreign matter Watson Laboratories Inc NDC 0591-5513-05 D-397-2014
Class I · High risk

Lidocaine HCl Injection

Presence of Particulate Matter- Confimed customer complaint of particulates embedded in glass container and in contact with product solution.

Terminated Particulate / foreign matter Hospira Inc. NDC 0409-2066-05 D-1278-2014
Class II · Moderate risk

Propofol Injectible Emulsion

Presence of Particulate Matter: Glass defect located on the interior neck of the vial identified glass surface abrasions and visible embedded particulate matter which could result in the potential for small glass flakes or embedded metal particulate to become dislodged into the solution.

Terminated Particulate / foreign matter Hospira Inc. NDC 0409-4699-30 D-1033-2014
Class II · Moderate risk

Carisoprodol IV

Presence of Foreign Substance; heavy metals (chromium, titanium etc) and inactive components of the product were visually observed during routine stability testing.

Terminated Particulate / foreign matter Physicians Total Care, Inc. D-390-2014